Loading
A phase 2 trial of Cemiplimab, Fianlimab in head and neck squamous cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06769698 by Regeneron Pharmaceuticals, with 120 participants planned, started 2026-04-14 and due to reach its primary completion in 2028-06-04. Interventions recorded: FDC fianlimab+cemiplimab, Cemiplimab, Placebo. Conditions listed: Head and Neck Squamous Cell Carcinoma (HNSCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/